Efficacy and Safety of Pyrotinib in Combination with Albumin‑bound Paclitaxel for the Treatment of HER2‑positive Advanced Breast Cancer: A Real‑world Study

Overview

Journal Oncol Lett

Specialty Oncology

Date 2023 Jun 19

PMID 37332328

Authors

Lixian Yang

Lei Zheng

Fanting Kong

Xinli Tian

Shiyu Zhang

Pengpeng Pu

Affiliations

Soon will be listed here.

Abstract

The present study aimed to determine the efficacy and safety of pyrotinib in combination with albumin-bound paclitaxel in patients with HER2-positive advanced breast cancer (ABC). A total of 48 patients diagnosed with HER2-positive ABC were included in the present study, and these patients were prescribed a combination of pyrotinib and albumin-bound paclitaxel in routine clinical practice. During a 21-day cycle, the standard dosage of pyrotinib was 400 mg single dose/day, which was administered orally, and 130 mg/m/day albumin-bound paclitaxel on days 1, 8 and 15, which was administered by intravenous drip. The primary efficacy endpoint was progression-free survival (PFS) and the secondary efficacy endpoint was overall response rate (ORR), which was defined as the percentage of patients with complete remission or partial remission. Safety indicators were also observed in the present study. The results of the present study demonstrated that the median PFS (mPFS) was 8.1 months for all patients, ranging from 3.3-10.6 months. Patients receiving pyrotinib as second-line therapy exhibited a longer mPFS of 8.5 months compared with those receiving it as third- or higher-line therapy (mPFS, 5.9 months). In 17 patients with brain metastases, mPFS was 7.3 months, ranging from 4.8-10.1 months. The results of the present study also demonstrated that the ORR for the 48 patients was 33.3%. Notably, diarrhea was the most common grade 3-4 adverse event, occurring in 22.9% of patients, followed by neutropenia (6.3%), leukopenia (4.2%) and anemia (4.2%). Collectively, the results of the present study indicated that pyrotinib-based treatment is effective for patients with HER2 ABC, including those who have previously been treated with trastuzumab. Thus, the combination of pyrotinib with albumin-bound paclitaxel is recommended due to high levels of efficacy, convenience and tolerability.

References

Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

Garcia-Alvarez A, Papakonstantinou A, Oliveira M . Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies. Cancers (Basel). 2021; 13(12). PMC: 8230933. DOI: 10.3390/cancers13122927. View

Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q . Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021; 22(3):351-360. DOI: 10.1016/S1470-2045(20)30702-6. View

Chen Q, Ouyang D, Anwar M, Xie N, Wang S, Fan P . Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis. Front Oncol. 2020; 10:811. PMC: 7263174. DOI: 10.3389/fonc.2020.00811. View

Freedman R, Gelman R, Anders C, Melisko M, Parsons H, Cropp A . TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2019; 37(13):1081-1089. PMC: 6494354. DOI: 10.1200/JCO.18.01511. View

Swain S, Baselga J, Miles D, Im Y, Quah C, Lee L . Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014; 25(6):1116-21. PMC: 4037862. DOI: 10.1093/annonc/mdu133. View

Brufsky A, Mayer M, Rugo H, Kaufman P, Tan-Chiu E, Tripathy D . Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011; 17(14):4834-43. DOI: 10.1158/1078-0432.CCR-10-2962. View

Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-92. DOI: 10.1056/NEJM200103153441101. View

Awada A, Colomer R, Inoue K, Bondarenko I, Badwe R, Demetriou G . Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial. JAMA Oncol. 2016; 2(12):1557-1564. DOI: 10.1001/jamaoncol.2016.0237. View

10.

Lin Y, Lin M, Zhang J, Wang B, Tao Z, Du Y . Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis. Cancer Res Treat. 2020; 52(4):1059-1066. PMC: 7577809. DOI: 10.4143/crt.2019.633. View

11.

Saura C, Oliveira M, Feng Y, Dai M, Chen S, Hurvitz S . Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial. J Clin Oncol. 2020; 38(27):3138-3149. PMC: 7499616. DOI: 10.1200/JCO.20.00147. View

12.

Gradishar W, Krasnojon D, Cheporov S, Makhson A, Manikhas G, Clawson A . Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clin Breast Cancer. 2012; 12(5):313-21. DOI: 10.1016/j.clbc.2012.05.001. View

13.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

14.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

15.

Wong H, Leung R, Kwong A, Chiu J, Liang R, Swanton C . Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer. Oncologist. 2011; 16(11):1535-46. PMC: 3233287. DOI: 10.1634/theoncologist.2011-0165. View

16.

Urruticoechea A, Rizwanullah M, Im S, Sanchez Ruiz A, Lang I, Tomasello G . Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based.... J Clin Oncol. 2017; 35(26):3030-3038. DOI: 10.1200/JCO.2016.70.6267. View

17.

Blows F, Driver K, Schmidt M, Broeks A, van Leeuwen F, Wesseling J . Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010; 7(5):e1000279. PMC: 2876119. DOI: 10.1371/journal.pmed.1000279. View

18.

Pohlmann P, Mayer I, Mernaugh R . Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res. 2009; 15(24):7479-7491. PMC: 3471537. DOI: 10.1158/1078-0432.CCR-09-0636. View

19.

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

20.

Olson E, Najita J, Sohl J, Arnaout A, Burstein H, Winer E . Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013; 22(4):525-31. PMC: 3713786. DOI: 10.1016/j.breast.2012.12.006. View

​Efficacy and Safety of Pyrotinib in Combination with Albumin‑bound Paclitaxel for the Treatment of HER2‑positive Advanced Breast Cancer: A Real‑world Study

Efficacy and Safety of Pyrotinib in Combination with Albumin‑bound Paclitaxel for the Treatment of HER2‑positive Advanced Breast Cancer: A Real‑world Study